- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04603300
OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut
Oral Mucosal Escalation Goal Assessment (OMEGA) Study: A Randomized Placebo-Controlled Phase 1 Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New Jersey
-
Belleville, New Jersey, United States, 07109
- Hudson-Essex Allergy
-
Riverdale, New Jersey, United States, 07457
- Weiss Medical
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participant must be 18-55 years of age inclusive, at the time of signing the informed consent.
Female participants of childbearing potential or male participants with female partners of child-bearing potential must utilize highly effective birth control method(s) throughout the study and for 30 days after the final dose of study drug. Acceptable methods of contraception include: complete abstinence, male or female condoms with spermicide, oral or implanted contraceptives, or vasectomy.
For female participants of child-bearing potential: Negative serum beta human chorionic gonadotrophin (HCG) pregnancy test at screening.
Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Meets at least one of the following conditions
- Positive skin prick test (SPT) (wheal at least 3 mm greater than control) AND/OR Peanut specific IgE >0.35 kU/L
- Convincing clinical history of allergic reaction to peanut within 1 hour of ingestion for at least 3 months prior to screening.
- Failed an oral food challenge (OFC) of < 100mg of peanut protein at screening.
- Participant willing and able to undergo the procedures required by the protocol, including, assessment completion, protocol compliance, and participation in the placebo dosing period(s).
Exclusion Criteria:
- History of severe anaphylaxis to peanut, defined as hypoxia, hypotension, or neurologic compromise (cyanosis or oxygen saturations < 92% at any stage, hypotension, confusion, collapse, loss of consciousness, or incontinence)
- Significant medical condition (e.g., liver, kidney, gastrointestinal, cardiovascular, hematologic, or pulmonary disease) which would make the subject unsuitable for induction of food reactions
- Eosinophilic or other inflammatory (e.g. celiac) gastrointestinal disease
- Psychiatric disorders that the Investigator believes will interfere with study assessments
Uncontrolled asthma, defined by at least one of the following conditions:
- - FEV1 <80% of predicted, or ratio of FEV1 to forced vital capacity (FEV1/FVC) <75% of predicted, with or without controller medications.
- - Inhaled corticosteroids (ICS) dosing of >500mcg daily fluticasone (or equivalent ICS based on NHLBI dosing chart.
- - One hospitalization in the past year for asthma
- - An ER visit for asthma within six months prior to screening
- Planned dental surgery during from screening until study exit
- Moderate or advanced periodontal disease.
- Current pregnancy or lactating
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active treatment
INT301 dosing as determined by cohort assignment
|
INT301 is an allergy immunotherapy delivered in the form of a fully functional toothpaste
|
Placebo Comparator: Placebo
Placebo as determined by cohort assignment
|
Fully functional toothpaste containing no immunotherapy agents
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the safety of INT301 compared to placebo in adult peanut allergic participants as measured by dose escalation during study.
Time Frame: Forty-eight weeks
|
Percentage of participants able to consistently tolerate the protocol-specified highest dose; Incidence of systemic and non-systemic adverse reactions.
|
Forty-eight weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate pharmacologic requirements as interventions for peanut allergic participants experiencing adverse events on INT301.
Time Frame: Forty-eight weeks
|
Number of participants requiring treatment for systemic reactions related to experimental treatment or placebo; Number of adverse events requiring treatment for systemic reactions related to experimental treatment or placebo; Adherence to study treatment.
|
Forty-eight weeks
|
To determine the maximally tolerated dose during the up-dosing phase for adults.
Time Frame: Twenty-six weeks
|
Dose amount tolerated without AEs requiring discontinuation for each participant.
|
Twenty-six weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To explore changes in peanut-specific IgG4, IgA, and IgE levels in participants (exploratory outcome).
Time Frame: Forty-eight weeks
|
Change from baseline of peanut-specific IgG4, IgA, and IgE in study subjects (exploratory outcome)
|
Forty-eight weeks
|
To explore changes in patient response to oral food challenge pre-treatment and post treatment.
Time Frame: Forty-eight weeks
|
Change from baseline of tolerated amount of peanut protein
|
Forty-eight weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- INT301-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peanut Allergy
-
Rima RachidUniversity of MinnesotaRecruitingPeanut Hypersensitivity | Peanut Allergy | Food Allergy | Food Allergy Peanut | Peanut-Induced Anaphylaxis | Allergy, PeanutUnited States
-
Scripps HealthThe Scripps Research InstituteWithdrawnFood Allergy PeanutUnited States
-
Novartis PharmaceuticalsTerminatedAllergy, PeanutUnited States, Germany, Japan, Australia, France, Spain, Denmark, Canada, Italy, Netherlands
-
University of ManitobaThe Hospital for Sick Children; University of British Columbia; McGill UniversityEnrolling by invitationAllergy to Peanut
-
Imperial College LondonUniversity of Sydney; National Institute for Health Research, United KingdomCompletedIgE Mediated Peanut AllergyUnited Kingdom
-
King's College LondonCharite University, Berlin, Germany; University Hospital, Bonn; Institut Curie; Levantine UKNot yet recruitingAllergy;Food | Food Allergy Peanut | Pathways and Sources of Exposure
-
Imperial College LondonUniversity College CorkActive, not recruitingPeanut Hypersensitivity | IgE Mediated Peanut AllergyUnited Kingdom
-
University of RochesterNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingEgg Allergy | Food Allergy Peanut | Food Allergy in Infants | Allergy and Immunology | Peanut and Nut AllergyUnited States
-
National Institute of Allergy and Infectious Diseases...Genentech, Inc.; Novartis Pharmaceuticals; Rho Federal Systems Division, Inc.Active, not recruitingPeanut Allergy | Multi-food AllergyUnited States
-
Scott SichererNational Institute of Allergy and Infectious Diseases (NIAID)CompletedPeanut Allergy | Food AllergyUnited States